Status:
COMPLETED
Visualising Cerebral and Peripheral Cholinergic Nerves in Patients With Dementia Lewy Bodies.
Lead Sponsor:
University of Aarhus
Conditions:
Dementia With Lewy Bodies
Degeneration Nerves
Eligibility:
All Genders
50-85 years
Brief Summary
Lewy Body Dementia (DLB) is the second most common type of neurodegenerative dementia and characterized by loss of cholinergic neurons in the cerebrum and possibly also internal organs. A novel tracer...
Detailed Description
Dementia with Lewy Bodies (DLB) is the second most common type of neurodegenerative dementia after Alzheimer's disease. It is characterized by cognitive decline, cognitive fluctuations, visual halluci...
Eligibility Criteria
Inclusion
- mild to moderate DLB, ability to give informed consent, and typical signs of DLB on an FDG-PET or dopamine transporter (DaT)-scan
Exclusion
- schizophrenia, bipolar disorder, cerebral neoplasms, clinical stroke, diabetes, peripheral neuropathy, previous surgery or radiotherapy on cerebrum or internal organs, gastrointestinal inflammatory disease, severe organ failure, allergy to CT-contrast media and contraindications to MRI-scans
Key Trial Info
Start Date :
February 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04291144
Start Date
February 1 2020
End Date
March 1 2023
Last Update
May 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear medicine and PET, Aarhus University Hospital
Aarhus N, Denmark, 8200